Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B.
about
Alpha-interferon for chronic hepatitis BAlpha-interferon for chronic hepatitis BBicyclol for chronic hepatitis BIntroduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data.Update on clinical trials in the treatment of hepatitis B.A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effectiveInterferon monotherapy in chronic hepatitis B.Epidemiology of primary and secondary liver cancers.The economics of treating chronic hepatitis B in Asia.Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway.Review article: current management of chronic hepatitis B.Emerging treatments in chronic hepatitis B.Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia.The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country.Therapy of hepatitis B -- viral suppression or eradication?Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B.A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B.Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: a systematic review of economic evidence.Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves.Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis.Health-state utilities in liver disease: a systematic review.Short-term intravenous interferon therapy for chronic hepatitis B.Is chronic hepatitis B being undertreated in the United States?Sourcing quality-of-life weights obtained from previous studies: theory and reality in Korea.Chronic viral hepatitis and use of interferon. Whom are we treating?Why we should treat chronic viral hepatitis.Modeling therapeutic benefit in the midst of uncertainty: therapy for hepatitis C.EUR-ASSESS Project Subgroup report on Methodology. Methodological guidance for the conduct of health technology assessment.Screening for hepatitis B carriers: a perspective from New Zealand.Retrospective analysis of total direct medical costs associated with hepatitis B patients with oral antiviral versus pegylated interferon therapy in Turkey.Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis.A preliminary experience with GM-CSF plus interferon in patients with HBV and HCV resistant to interferon therapy.Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.Cost-Effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma.Hepatitis B virus infection among refugees resettled in the U.S.: high prevalence and challenges in access to health care.Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B.Activity-based costs of blood transfusions in surgical patients at four hospitals.Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis.Hepatitis B virus-related hepatocellular carcinogenesis and its prevention.Significance of hepatitis B virus DNA clearance and early prediction of hepatocellular carcinogenesis in patients with cirrhosis undergoing interferon therapy: long-term follow up of a pilot study.
P2860
Q24236641-F0B61726-0846-45F7-B13D-24E4F3D0157BQ24240563-00403120-5EBD-4386-8AEE-AB35706ACEBBQ24247903-96315844-7D9A-4579-89C3-BCB628AFE4B5Q30689186-45B63AE2-5D93-4D79-9C0E-36B8A3530D69Q33670329-F927AEB8-E154-4F3B-B50A-A1866DCE39A7Q33804151-F19C14A5-B8B5-415A-BBEA-64B97C1CC20AQ33988044-90C21B42-3B7E-49AA-812E-E0DF7F40A87CQ34563350-055882C5-E4E5-4C05-8395-BD247CE76698Q34996644-B3785292-AC77-411A-A877-FB3C55D14E1EQ35098611-0E74B705-A9A7-4852-98C8-DE826DB84E14Q35612108-02550C08-97BB-4E33-9FD8-9FF383FBAF36Q35967369-563FC801-0417-4989-A945-BFF4745B62DBQ36115014-51C9423C-1719-488D-B7C0-79D724625426Q36189795-71EDEA31-A812-466E-8148-9244C44E143DQ36382226-8FC4CBAC-D6BF-4197-A8FB-9B1EB3FC1CD9Q36622996-15AF0038-3CE2-48DD-AFF0-CA6E0C7CE2D9Q36715901-ACF27AE8-3B2D-4942-9774-FA40D2707183Q36918239-C554B327-8ADB-4992-BEBC-F5E2E0139884Q37084602-1E1C8BA2-26ED-40B8-BB9F-D5533270CF78Q37121872-E1CEF67C-3B8E-4F82-BCF1-445456CCFEF6Q37142994-4D22F601-CEB9-4208-B07C-870C2139E224Q37265596-6A0B080F-BEBD-4FD4-9314-8541E9A315B2Q37818488-6B9D564E-6299-4F88-B353-7CB83C9E6C46Q38191873-B003F020-DFD2-4CED-BB6E-E946A38FA179Q41104322-C7E0E8EA-BBA1-4CFF-A7FF-F6091C3B8A92Q41104327-40D38080-269E-4DB5-8214-1865C0842A70Q41332820-BB130174-9C58-484A-879B-60EB9CD670C1Q41508198-C235A271-576E-4B80-B14C-EED2BFD3D60CQ41712947-3664F09C-18B3-4E59-BDC8-51EDDD3FAA05Q42236429-A6BAC64F-2AF7-4DFC-9433-752537B40D03Q42248537-4D7082B0-2AD4-4B1F-84EF-F63924E99184Q42653049-62389706-42A3-42F4-B6C8-342D9FC62672Q43133532-E5861DFF-68E9-4685-9D50-B5E4F743AF7CQ43653707-DDE4298E-DB1A-47BC-8D01-E478329B2990Q44689974-7B42CDB2-CF3C-4B87-B201-9D69921D5EC9Q44961359-1A650D32-1437-4297-8D0A-22A44448B417Q45338873-7B5B0BCA-2430-4CE7-B44D-60657168BD64Q45407427-A5395BC5-8C70-49E1-AB86-479F66AE6BD6Q45492244-25BE99E0-7687-4D8B-90E0-1C439FE4BC70Q45532567-96C0D4B7-48D1-4085-8646-1CAC28BA8C78
P2860
Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Cost-effectiveness of interfer ...... -positive chronic hepatitis B.
@en
type
label
Cost-effectiveness of interfer ...... -positive chronic hepatitis B.
@en
prefLabel
Cost-effectiveness of interfer ...... -positive chronic hepatitis B.
@en
P2093
P1476
Cost-effectiveness of interfer ...... -positive chronic hepatitis B.
@en
P2093
P304
P356
10.7326/0003-4819-122-9-199505010-00004
P407
P577
1995-05-01T00:00:00Z